Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

Anna Morra; Maartje A C Schreurs; Irene L Andrulis; Hoda Anton-Culver; Annelie Augustinsson; Matthias W Beckmann; Sabine Behrens; Stig E Bojesen; Manjeet K Bolla; Hiltrud Brauch; Annegien Broeks; Saundra S Buys; Nicola J Camp; Jose E Castelao; Melissa H Cessna; Jenny Chang-Claude; Wendy K Chung; Nbcs Collaborators; Sarah V Colonna; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Mary B Daly; Joe Dennis; Peter Devilee; Thilo Dörk; Alison M Dunning; Miriam Dwek; Douglas F Easton; Diana M Eccles; Mikael Eriksson; D Gareth Evans; Peter A Fasching; Tanja N Fehm; Jonine D Figueroa; Henrik Flyger; Marike Gabrielson; Manuela Gago-Dominguez; Montserrat García-Closas; José A García-Sáenz; Jeanine Genkinger; Felix Grassmann; Melanie Gündert; Eric Hahnen; Christopher A Haiman; Ute Hamann; Patricia A Harrington; Jaana M Hartikainen; Reiner Hoppe; John L Hopper; Richard S Houlston; Anthony Howell; Anna Jakubowska; Wolfgang Janni; Helena Jernström; Esther M John; Nichola Johnson; Michael E Jones; Vessela N Kristensen; Allison W Kurian; Diether Lambrechts; Loic Le Marchand; Annika Lindblom; Jan Lubiński; Michael P Lux; Arto Mannermaa; Dimitrios Mavroudis; Anna Marie Mulligan; Taru A Muranen; Heli Nevanlinna; Ines Nevelsteen; Patrick Neven; William G Newman; Nadia Obi; Kenneth Offit; Andrew F Olshan; Tjoung-Won Park-Simon; Alpa V Patel; Paolo Peterlongo; Kelly-Anne Phillips; Dijana Plaseska-Karanfilska; Eric C Polley; Nadege Presneau; Katri Pylkäs; Brigitte Rack; Paolo Radice; Muhammad U Rashid; Valerie Rhenius; Mark Robson; Atocha Romero; Emmanouil Saloustros; Elinor J Sawyer; Rita K Schmutzler; Sabine Schuetze; Christopher Scott; Mitul Shah; Snezhana Smichkoska; Melissa C Southey; William J Tapper; Lauren R Teras; Rob A E M Tollenaar; Katarzyna Tomczyk; Ian Tomlinson; Melissa A Troester; Celine M Vachon; Elke M van Veen; Qin Wang; Camilla Wendt; Hans Wildiers; Robert Winqvist; Argyrios Ziogas; Per Hall; Paul D P Pharoah; Muriel A Adank; Antoinette Hollestelle; Marjanka K Schmidt; Maartje J Hooning; ABCTB Investigators; KConFab Investigators

doi:10.1002/cam4.6272

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

Standard

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. / Morra, Anna; Schreurs, Maartje A C; Andrulis, Irene L; Anton-Culver, Hoda; Augustinsson, Annelie; Beckmann, Matthias W; Behrens, Sabine; Bojesen, Stig E; Bolla, Manjeet K; Brauch, Hiltrud; Broeks, Annegien; Buys, Saundra S; Camp, Nicola J; Castelao, Jose E; Cessna, Melissa H; Chang-Claude, Jenny; Chung, Wendy K; Collaborators, Nbcs; Colonna, Sarah V; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Daly, Mary B; Dennis, Joe; Devilee, Peter; Dörk, Thilo; Dunning, Alison M; Dwek, Miriam; Easton, Douglas F; Eccles, Diana M; Eriksson, Mikael; Evans, D Gareth; Fasching, Peter A; Fehm, Tanja N; Figueroa, Jonine D; Flyger, Henrik; Gabrielson, Marike; Gago-Dominguez, Manuela; García-Closas, Montserrat; García-Sáenz, José A; Genkinger, Jeanine; Grassmann, Felix; Gündert, Melanie; Hahnen, Eric; Haiman, Christopher A; Hamann, Ute; Harrington, Patricia A; Hartikainen, Jaana M; Hoppe, Reiner; Hopper, John L; Houlston, Richard S; Howell, Anthony; Jakubowska, Anna; Janni, Wolfgang; Jernström, Helena; John, Esther M; Johnson, Nichola; Jones, Michael E; Kristensen, Vessela N; Kurian, Allison W; Lambrechts, Diether; Marchand, Loic Le; Lindblom, Annika; Lubiński, Jan; Lux, Michael P; Mannermaa, Arto; Mavroudis, Dimitrios; Mulligan, Anna Marie; Muranen, Taru A; Nevanlinna, Heli; Nevelsteen, Ines; Neven, Patrick; Newman, William G; Obi, Nadia; Offit, Kenneth; Olshan, Andrew F; Park-Simon, Tjoung-Won; Patel, Alpa V; Peterlongo, Paolo; Phillips, Kelly-Anne; Plaseska-Karanfilska, Dijana; Polley, Eric C; Presneau, Nadege; Pylkäs, Katri; Rack, Brigitte; Radice, Paolo; Rashid, Muhammad U; Rhenius, Valerie; Robson, Mark; Romero, Atocha; Saloustros, Emmanouil; Sawyer, Elinor J; Schmutzler, Rita K; Schuetze, Sabine; Scott, Christopher; Shah, Mitul; Smichkoska, Snezhana; Southey, Melissa C; Tapper, William J; Teras, Lauren R; Tollenaar, Rob A E M; Tomczyk, Katarzyna; Tomlinson, Ian; Troester, Melissa A; Vachon, Celine M; van Veen, Elke M; Wang, Qin; Wendt, Camilla; Wildiers, Hans; Winqvist, Robert; Ziogas, Argyrios; Hall, Per; Pharoah, Paul D P; Adank, Muriel A; Hollestelle, Antoinette; Schmidt, Marjanka K; Hooning, Maartje J; ABCTB Investigators; KConFab Investigators.

in: CANCER MED-US, Jahrgang 12, Nr. 15, 13.02.2023, S. 16142-16162.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Morra, A, Schreurs, MAC, Andrulis, IL, Anton-Culver, H, Augustinsson, A, Beckmann, MW, Behrens, S, Bojesen, SE, Bolla, MK, Brauch, H, Broeks, A, Buys, SS, Camp, NJ, Castelao, JE, Cessna, MH, Chang-Claude, J, Chung, WK, Collaborators, N, Colonna, SV, Couch, FJ, Cox, A, Cross, SS, Czene, K, Daly, MB, Dennis, J, Devilee, P, Dörk, T, Dunning, AM, Dwek, M, Easton, DF, Eccles, DM, Eriksson, M, Evans, DG, Fasching, PA, Fehm, TN, Figueroa, JD, Flyger, H, Gabrielson, M, Gago-Dominguez, M, García-Closas, M, García-Sáenz, JA, Genkinger, J, Grassmann, F, Gündert, M, Hahnen, E, Haiman, CA, Hamann, U, Harrington, PA, Hartikainen, JM, Hoppe, R, Hopper, JL, Houlston, RS, Howell, A, Jakubowska, A, Janni, W, Jernström, H, John, EM, Johnson, N, Jones, ME, Kristensen, VN, Kurian, AW, Lambrechts, D, Marchand, LL, Lindblom, A, Lubiński, J, Lux, MP, Mannermaa, A, Mavroudis, D, Mulligan, AM, Muranen, TA, Nevanlinna, H, Nevelsteen, I, Neven, P, Newman, WG, Obi, N, Offit, K, Olshan, AF, Park-Simon, T-W, Patel, AV, Peterlongo, P, Phillips, K-A, Plaseska-Karanfilska, D, Polley, EC, Presneau, N, Pylkäs, K, Rack, B, Radice, P, Rashid, MU, Rhenius, V, Robson, M, Romero, A, Saloustros, E, Sawyer, EJ, Schmutzler, RK, Schuetze, S, Scott, C, Shah, M, Smichkoska, S, Southey, MC, Tapper, WJ, Teras, LR, Tollenaar, RAEM, Tomczyk, K, Tomlinson, I, Troester, MA, Vachon, CM, van Veen, EM, Wang, Q, Wendt, C, Wildiers, H, Winqvist, R, Ziogas, A, Hall, P, Pharoah, PDP, Adank, MA, Hollestelle, A, Schmidt, MK, Hooning, MJ, ABCTB Investigators & KConFab Investigators 2023, 'Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival', CANCER MED-US, Jg. 12, Nr. 15, S. 16142-16162. https://doi.org/10.1002/cam4.6272

APA

Morra, A., Schreurs, M. A. C., Andrulis, I. L., Anton-Culver, H., Augustinsson, A., Beckmann, M. W., Behrens, S., Bojesen, S. E., Bolla, M. K., Brauch, H., Broeks, A., Buys, S. S., Camp, N. J., Castelao, J. E., Cessna, M. H., Chang-Claude, J., Chung, W. K., Collaborators, N., Colonna, S. V., ... KConFab Investigators (2023). Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. CANCER MED-US, 12(15), 16142-16162. https://doi.org/10.1002/cam4.6272

Vancouver

Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW et al. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. CANCER MED-US. 2023 Feb 13;12(15):16142-16162. https://doi.org/10.1002/cam4.6272

Bibtex

@article{95d6a59dedd44f96b02cc68ae98ecf2c,

title = "Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival",

abstract = "Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55-0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09-1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words).",

author = "Anna Morra and Schreurs, {Maartje A C} and Andrulis, {Irene L} and Hoda Anton-Culver and Annelie Augustinsson and Beckmann, {Matthias W} and Sabine Behrens and Bojesen, {Stig E} and Bolla, {Manjeet K} and Hiltrud Brauch and Annegien Broeks and Buys, {Saundra S} and Camp, {Nicola J} and Castelao, {Jose E} and Cessna, {Melissa H} and Jenny Chang-Claude and Chung, {Wendy K} and Nbcs Collaborators and Colonna, {Sarah V} and Couch, {Fergus J} and Angela Cox and Cross, {Simon S} and Kamila Czene and Daly, {Mary B} and Joe Dennis and Peter Devilee and Thilo D{\"o}rk and Dunning, {Alison M} and Miriam Dwek and Easton, {Douglas F} and Eccles, {Diana M} and Mikael Eriksson and Evans, {D Gareth} and Fasching, {Peter A} and Fehm, {Tanja N} and Figueroa, {Jonine D} and Henrik Flyger and Marike Gabrielson and Manuela Gago-Dominguez and Montserrat Garc{\'i}a-Closas and Garc{\'i}a-S{\'a}enz, {Jos{\'e} A} and Jeanine Genkinger and Felix Grassmann and Melanie G{\"u}ndert and Eric Hahnen and Haiman, {Christopher A} and Ute Hamann and Harrington, {Patricia A} and Hartikainen, {Jaana M} and Reiner Hoppe and Hopper, {John L} and Houlston, {Richard S} and Anthony Howell and Anna Jakubowska and Wolfgang Janni and Helena Jernstr{\"o}m and John, {Esther M} and Nichola Johnson and Jones, {Michael E} and Kristensen, {Vessela N} and Kurian, {Allison W} and Diether Lambrechts and Marchand, {Loic Le} and Annika Lindblom and Jan Lubi{\'n}ski and Lux, {Michael P} and Arto Mannermaa and Dimitrios Mavroudis and Mulligan, {Anna Marie} and Muranen, {Taru A} and Heli Nevanlinna and Ines Nevelsteen and Patrick Neven and Newman, {William G} and Nadia Obi and Kenneth Offit and Olshan, {Andrew F} and Tjoung-Won Park-Simon and Patel, {Alpa V} and Paolo Peterlongo and Kelly-Anne Phillips and Dijana Plaseska-Karanfilska and Polley, {Eric C} and Nadege Presneau and Katri Pylk{\"a}s and Brigitte Rack and Paolo Radice and Rashid, {Muhammad U} and Valerie Rhenius and Mark Robson and Atocha Romero and Emmanouil Saloustros and Sawyer, {Elinor J} and Schmutzler, {Rita K} and Sabine Schuetze and Christopher Scott and Mitul Shah and Snezhana Smichkoska and Southey, {Melissa C} and Tapper, {William J} and Teras, {Lauren R} and Tollenaar, {Rob A E M} and Katarzyna Tomczyk and Ian Tomlinson and Troester, {Melissa A} and Vachon, {Celine M} and {van Veen}, {Elke M} and Qin Wang and Camilla Wendt and Hans Wildiers and Robert Winqvist and Argyrios Ziogas and Per Hall and Pharoah, {Paul D P} and Adank, {Muriel A} and Antoinette Hollestelle and Schmidt, {Marjanka K} and Hooning, {Maartje J} and {ABCTB Investigators} and {KConFab Investigators} and Volker Harth",

year = "2023",

month = feb,

day = "13",

doi = "10.1002/cam4.6272",

language = "English",

volume = "12",

pages = "16142--16162",

journal = "CANCER MED-US",

issn = "2045-7634",

publisher = "John Wiley and Sons Ltd",

number = "15",

}

RIS

TY - JOUR

T1 - Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

AU - Morra, Anna

AU - Schreurs, Maartje A C

AU - Andrulis, Irene L

AU - Anton-Culver, Hoda

AU - Augustinsson, Annelie

AU - Beckmann, Matthias W

AU - Behrens, Sabine

AU - Bojesen, Stig E

AU - Bolla, Manjeet K

AU - Brauch, Hiltrud

AU - Broeks, Annegien

AU - Buys, Saundra S

AU - Camp, Nicola J

AU - Castelao, Jose E

AU - Cessna, Melissa H

AU - Chang-Claude, Jenny

AU - Chung, Wendy K

AU - Collaborators, Nbcs

AU - Colonna, Sarah V

AU - Couch, Fergus J

AU - Cox, Angela

AU - Cross, Simon S

AU - Czene, Kamila

AU - Daly, Mary B

AU - Dennis, Joe

AU - Devilee, Peter

AU - Dörk, Thilo

AU - Dunning, Alison M

AU - Dwek, Miriam

AU - Easton, Douglas F

AU - Eccles, Diana M

AU - Eriksson, Mikael

AU - Evans, D Gareth

AU - Fasching, Peter A

AU - Fehm, Tanja N

AU - Figueroa, Jonine D

AU - Flyger, Henrik

AU - Gabrielson, Marike

AU - Gago-Dominguez, Manuela

AU - García-Closas, Montserrat

AU - García-Sáenz, José A

AU - Genkinger, Jeanine

AU - Grassmann, Felix

AU - Gündert, Melanie

AU - Hahnen, Eric

AU - Haiman, Christopher A

AU - Hamann, Ute

AU - Harrington, Patricia A

AU - Hartikainen, Jaana M

AU - Hoppe, Reiner

AU - Hopper, John L

AU - Houlston, Richard S

AU - Howell, Anthony

AU - Jakubowska, Anna

AU - Janni, Wolfgang

AU - Jernström, Helena

AU - John, Esther M

AU - Johnson, Nichola

AU - Jones, Michael E

AU - Kristensen, Vessela N

AU - Kurian, Allison W

AU - Lambrechts, Diether

AU - Marchand, Loic Le

AU - Lindblom, Annika

AU - Lubiński, Jan

AU - Lux, Michael P

AU - Mannermaa, Arto

AU - Mavroudis, Dimitrios

AU - Mulligan, Anna Marie

AU - Muranen, Taru A

AU - Nevanlinna, Heli

AU - Nevelsteen, Ines

AU - Neven, Patrick

AU - Newman, William G

AU - Obi, Nadia

AU - Offit, Kenneth

AU - Olshan, Andrew F

AU - Park-Simon, Tjoung-Won

AU - Patel, Alpa V

AU - Peterlongo, Paolo

AU - Phillips, Kelly-Anne

AU - Plaseska-Karanfilska, Dijana

AU - Polley, Eric C

AU - Presneau, Nadege

AU - Pylkäs, Katri

AU - Rack, Brigitte

AU - Radice, Paolo

AU - Rashid, Muhammad U

AU - Rhenius, Valerie

AU - Robson, Mark

AU - Romero, Atocha

AU - Saloustros, Emmanouil

AU - Sawyer, Elinor J

AU - Schmutzler, Rita K

AU - Schuetze, Sabine

AU - Scott, Christopher

AU - Shah, Mitul

AU - Smichkoska, Snezhana

AU - Southey, Melissa C

AU - Tapper, William J

AU - Teras, Lauren R

AU - Tollenaar, Rob A E M

AU - Tomczyk, Katarzyna

AU - Tomlinson, Ian

AU - Troester, Melissa A

AU - Vachon, Celine M

AU - van Veen, Elke M

AU - Wang, Qin

AU - Wendt, Camilla

AU - Wildiers, Hans

AU - Winqvist, Robert

AU - Ziogas, Argyrios

AU - Hall, Per

AU - Pharoah, Paul D P

AU - Adank, Muriel A

AU - Hollestelle, Antoinette

AU - Schmidt, Marjanka K

AU - Hooning, Maartje J

AU - ABCTB Investigators

AU - KConFab Investigators

AU - Harth, Volker

PY - 2023/2/13

Y1 - 2023/2/13

N2 - Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55-0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09-1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words).

AB - Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. We aimed to assess the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. Analyses were based on 82,701 women diagnosed with invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations of treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR(95%CI): 0.66 (0.55-0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR(95%CI) :1.30 (1.09-1.56)]. In conclusion, systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk. (Main MS: 3201 words).

U2 - 10.1002/cam4.6272

DO - 10.1002/cam4.6272

M3 - SCORING: Journal article

C2 - 36824750

VL - 12

SP - 16142

EP - 16162

JO - CANCER MED-US

JF - CANCER MED-US

SN - 2045-7634

IS - 15

ER -